Your browser is no longer supported. Please, upgrade your browser.
Settings
VRX Valeant Pharmaceuticals International, Inc. daily Stock Chart
VRX [NYSE]
Valeant Pharmaceuticals International, Inc.
Index- P/E- EPS (ttm)-6.49 Insider Own2.30% Shs Outstand345.41M Perf Week-10.89%
Market Cap4.69B Forward P/E2.64 EPS next Y5.15 Insider Trans-30.39% Shs Float332.27M Perf Month-4.37%
Income-2256.30M PEG- EPS next Q1.21 Inst Own66.80% Short Float8.75% Perf Quarter-38.16%
Sales10.01B P/S0.47 EPS this Y-133.00% Inst Trans20.38% Short Ratio1.50 Perf Half Y-40.57%
Book/sh11.92 P/B1.14 EPS next Y-5.19% ROA-4.70% Target Price24.08 Perf Year-85.34%
Cash/sh1.91 P/C7.12 EPS next 5Y11.07% ROE-42.90% 52W Range13.00 - 101.40 Perf YTD-6.47%
Dividend- P/FCF12.08 EPS past 5Y4.40% ROI3.70% 52W High-86.61% Beta-0.17
Dividend %- Quick Ratio1.10 Sales past 5Y54.60% Gross Margin73.80% 52W Low4.46% ATR0.72
Employees22000 Current Ratio1.50 Sales Q/Q-11.00% Oper. Margin-5.20% RSI (14)33.38 Volatility4.09% 4.63%
OptionableYes Debt/Eq7.31 EPS Q/Q- Profit Margin-22.50% Rel Volume0.73 Prev Close13.99
ShortableYes LT Debt/Eq7.29 EarningsFeb 07 BMO Payout- Avg Volume19.39M Price13.58
Recom3.00 SMA20-9.29% SMA50-13.26% SMA200-42.03% Volume14,153,751 Change-2.93%
Jan-04-17Reiterated Piper Jaffray Underweight $16 → $11
Dec-15-16Downgrade Morgan Stanley Overweight → Equal-Weight $25 → $17
Nov-23-16Downgrade Mizuho Neutral → Underperform $25 → $11
Nov-14-16Reiterated Deutsche Bank Hold $29 → $24
Nov-10-16Reiterated Morgan Stanley Overweight $42 → $25
Nov-10-16Downgrade Rodman & Renshaw Buy → Neutral $81 → $23
Nov-09-16Reiterated RBC Capital Mkts Sector Perform $35 → $29
Oct-14-16Reiterated Deutsche Bank Hold $30 → $29
Oct-12-16Reiterated RBC Capital Mkts Sector Perform $36 → $35
Sep-20-16Resumed Deutsche Bank Hold $30
Aug-17-16Upgrade Morgan Stanley Equal-Weight → Overweight $33 → $42
Aug-15-16Upgrade Mizuho Underperform → Neutral $11 → $25
Aug-10-16Reiterated RBC Capital Mkts Sector Perform $31 → $36
Aug-10-16Reiterated Piper Jaffray Underweight $19 → $22
Aug-09-16Reiterated Rodman & Renshaw Buy $90 → $81
Jun-23-16Downgrade JP Morgan Overweight → Neutral
Jun-08-16Reiterated Stifel Buy $65 → $55
Jun-08-16Reiterated RBC Capital Mkts Sector Perform $58 → $33
Jun-08-16Reiterated Mizuho Underperform $18 → $11
May-03-16Reiterated Rodman & Renshaw Buy $105 → $102
Jan-24-17 03:46PM  Options Insight: How to Play Valeant
09:16AM  New Strong Sell Stocks for January 24th
Jan-23-17 02:45PM  Analysts dismiss Citron's sour take on TransDigm -5.02%
Jan-21-17 02:42PM  What Will Valeant Pharmaceuticals Sell Off Next? at Motley Fool
02:20PM  A Fond Farewell
Jan-20-17 03:31PM  Short-Seller Andrew Left Says Trump Should Target This Aerospace Stock
12:12PM  Why TransDigm Stock Tumbled 12% Today at Motley Fool
Jan-18-17 04:27PM  Dealpolitik: SEC Tilts Playing Field Against Targets of Hostile Bids at The Wall Street Journal
Jan-17-17 06:19PM  Short Sellers Now Fleeing Valeant Stock at Investopedia
05:49PM  [$$] Allergan Admits to Disclosure Violations During Valeant Bid at The Wall Street Journal
04:44PM  Bill Ackman Eases Into the New Year at Investopedia
07:37AM  Mario Gabelli on Viacom: Potential Growth in the Media Sector
Jan-13-17 04:39PM  Will This Be a Genius or Foolish Move for Johnson & Johnson? at Motley Fool
10:33AM  The strange deal 2 drug makers had over a medicine with a skyrocketing price
06:02AM  Pharma Stock Roundup: Trump Targets Pharma Again, Merck Up on Keytruda News
Jan-12-17 02:35PM  ETFs with exposure to Valeant Pharmaceuticals International, Inc. : January 12, 2017
11:33AM  Is Valeant Pharmaceuticals Intl Inc (VRX) Stock Back From The Dead? at Insider Monkey
10:19AM  Valeant Pharmaceuticals International, Inc. Value Analysis (NYSE:VRX) : January 12, 2017
09:37AM  12 Health Benefits of Medical Marijuana According To Publicly Traded Weed Companies at Insider Monkey
07:35AM  Trump criticism leads to falling stock prices at these Tampa employers at bizjournals.com
07:15AM  Deja Vu for Drug Stocks as Trump Slams Drug Pricing Again
Jan-11-17 04:54PM  Valeant Pharmaceuticals: Separating Fact From Fiction at Motley Fool -6.52%
04:42PM  Valeant Streamlines Portfolio with Skincare Brands Sale
04:21PM  Drug Stocks Tank As Trump Vows To Attack High Drug Prices
03:22PM  Wednesdays Top Biopharma Movers
02:51PM  Valeant's CEO Tries to Pitch Wall Street On the 'New Valeant' Being Very Different
12:40PM  Valeant Pharmaceuticals: Now Comes the Hard Part at Barrons.com
10:15AM  Valeant Pharmaceuticals: 'A Long Road to Recovery' at Barrons.com
09:30AM  Latest Research Reports on Market Movers Valeant Pharmaceuticals and Chipotle Mexican Grill Accesswire
08:40AM  Do Options Traders Know Something About Valeant Pharmaceuticals (VRX) Stock We Don't?
08:15AM  Blog Coverage Valeant Sells-Off Its Skin Care Brands to L'Oreal Accesswire
07:41AM  This Is the Smartest Move Valeant Pharmaceuticals Has Made in a Really Long Time at Motley Fool
07:30AM  Valeant Pharmaceuticals International, Inc. breached its 50 day moving average in a Bullish Manner : VRX-US : January 11, 2017
06:25AM  Valeant Soars 14% on $2.12B Worth of Asset Sales at Investopedia
12:07AM  [$$] LOréal Looks to Gain U.S. Share by Buying Valeant Brands at The Wall Street Journal
Jan-10-17 06:15PM  Celebrate One Debacle of a Merger With Another -- ICYMI +6.84%
05:11PM  VALEANT PHARMACEUTICALS INTERNATIONAL, INC. Files SEC form 8-K, Results of Operations and Financial Condition
05:08PM  Valeant Sells $2.1 Billion in Assets to Ease Debt Burden
05:06PM  'Valeant Sale One of Many That Need to Get Done'
04:55PM  Nasdaq closes at 4th straight recordmarks best such streak since 1999 at MarketWatch
04:49PM  CANADA STOCKS-TSX rises with financials and materials; Valeant jumps
04:21PM  Jaguar Animal Health, Inc. (NAS:JAGX) Given Company Update by Aegis Capital Corp. ABN Newswire
04:08PM  CANADA STOCKS-TSX rises with financials and materials groups
03:30PM  Tuesdays Top Biopharma Movers
03:05PM  Valeant lessens debt load with billion-dollar L'Oréal deal at bizjournals.com
02:07PM  Valeant: A Solid Price? at Barrons.com
02:06PM  Valeant Pharmaceuticals International, Inc -- Moody's: Valeant asset sales credit positive at Moody's
01:40PM  Will This Cure What Ails Valeant Pharmaceuticals? at Motley Fool
01:14PM  [$$] Valeant: on the rebound at Financial Times
12:38PM  Valeant Gets Breathing Room But Little Else at Bloomberg
12:32PM  Here's What Valeant Could Still Divest
12:20PM  Markets Look to Trump's News Conference
12:11PM  Why Valeant Pharmaceuticals Stock Is Jumping Today at Motley Fool
11:43AM  Charts of the day: Valeant shares jump, Chipotle climbs on sales trend
11:12AM  Valeant's Asset Sale To L'Oreal Explained
11:05AM  Why Valeant Is Making a Run
10:44AM  Valeant Turns Assets to Cash With $2.1 Billion in Deals
10:44AM  Valeant Turns Assets to Cash With $2.1 Billion in Deals at Bloomberg
10:41AM  Top Biotech Resolutions for 2017 at Motley Fool
10:31AM  Valeant: A Good Start? at Barrons.com
10:24AM  CANADA STOCKS-TSX rises with materials stocks; Valeant jumps
10:16AM  Valeant unloads more assets, Goldman Sachs gets downgraded, Yahoo changes coming
10:12AM  Stocks Mixed; Why Are Illumina, Valeant, Barracuda Soaring?
10:09AM  L'Oreal Buys Skincare Lines From Valeant for $1.3 Billion -- and Jim Cramer Comments
09:49AM  Valeant to Sell Dendreon Unit to Sanpower for $820 Million
09:49AM  Valeant Stock Gains on Possible Salix Interest at Investopedia
09:28AM  [$$] L'Oréal Looks to Gain U.S. Share by Buying Valeant Brands at The Wall Street Journal
09:19AM  Stocks to Watch: Yahoo, Chipotle, Valeant at The Wall Street Journal
08:38AM  3 Tempting Stocks We're Avoiding at Motley Fool
08:14AM  Small businesses feel great, dealmaking on a tear and World Cup growth
07:59AM  Valeant sells $2B in assets to begin paying down debt
07:51AM  Early movers: YHOO, VRX, CUDA, UNH, BABA, JNJ, GS & more at CNBC
07:11AM  L'Oreal's Pricey Problem Solvers at Bloomberg
06:57AM  [$$] Valeant raises $2.1bn through asset sales at Financial Times
06:00AM  Valeant Pharmaceuticals Announces Results Of Second Phase 3 Study For Psoriasis Treatment IDP-118 PR Newswire
06:00AM  Valeant Pharmaceuticals Announces Results Of Second Phase 3 Study For Psoriasis Treatment IDP-118 CNW Group
06:00AM  Bausch + Lomb Launches Expanded Parameters For Bausch + Lomb ULTRA® For Presbyopia Contact Lenses PR Newswire
06:00AM  Bausch + Lomb Launches Expanded Parameters For Bausch + Lomb ULTRA® For Presbyopia Contact Lenses CNW Group
03:17AM  Valeant To Sell CeraVe, AcneFree And AMBI Skincare Brands To L'Oreal For $1.3 Billion PR Newswire
03:17AM  Valeant To Sell CeraVe, AcneFree And AMBI Skincare Brands To L'Oreal For $1.3 Billion CNW Group
02:46AM  Valeant to Sell $2.1 Billion in Assets to Pay Down Debt at Bloomberg
01:02AM  [$$] Valeant Agrees to Sell Dendreon to Sanpower for $820 Million at The Wall Street Journal
12:08AM  Valeant To Sell Dendreon Cancer Business To China's Sanpower For $820 Million Cash at Barrons.com
Jan-09-17 11:45PM  Valeant to sell Dendreon unit to China's Sanpower for $820 mln Reuters
11:29PM  [$$] Valeant Agrees to Sell Dendreon to Sanpower for $820 Million at The Wall Street Journal
10:58PM  Valeant to sell Dendreon unit to China's Sanpower for $819.9 mln
10:54PM  Valeant to sell its Dendreon cancer business to China's Sanpower at MarketWatch
10:40PM  Valeant To Sell Dendreon To Sanpower Group For $819.9 Million In Cash PR Newswire
10:40PM  Valeant To Sell Dendreon To Sanpower Group For $819.9 Million In Cash CNW Group
04:58PM  Valeant hiked prices for a dizzying number of drugs last week
12:51PM  Why Valeant Stock Rose 5.5% Last Week at Investopedia
Jan-08-17 02:13PM  What If You Considered Gilead Sciences a Start-Up? at Motley Fool
Jan-07-17 04:20PM  5 Destroyed Stocks That Could Be Major Buys In 2017
Jan-06-17 01:59PM  The Biggest Hedge Fund Failures of 2016 at Investopedia
10:22AM  The Laundry List of Reasons Why Valeant Pharmaceuticals Intl. Inc. Plummeted 86% in 2016 at Motley Fool
Jan-05-17 10:30AM  Six Happenings You Won't Want to miss when 'Frisco Takes Center Stage in Healthcare
Jan-04-17 05:03PM  VALEANT PHARMACEUTICALS INTERNATIONAL, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Financial
04:30PM  Valeant Pharmaceuticals To Present At The 35th Annual J.P. Morgan Healthcare Conference PR Newswire
04:30PM  Valeant Pharmaceuticals To Present At The 35th Annual J.P. Morgan Healthcare Conference CNW Group
04:21PM  How Trump-related uncertainty is bringing out the health-care stock bears at MarketWatch
Valeant Pharmaceuticals International, Inc. develops, manufactures, and markets pharmaceuticals, over-the-counter products, and medical devices worldwide. The company offers Xifaxan for the treatment of irritable bowel syndrome with diarrhea; Wellbutrin XL for major depressive disorder in adults; Solodyn to treat red and pus-filled pimples of acne in patients, as well as Ziana, Clindagel, Acanya, Atralin, Retin- A Micro, and ONEXTON gel; Glumetza to improve glycemic control in adults with type 2 diabetes mellitus; PROVENGE for the treatment of prostate cancer; and Jublia for onychomycosis of the toenails. It also provides Nitropress for the immediate reduction of blood pressure of patients in hypertensive crises; Isuprel for heart related treatments; Xenazine for chorea; Uceris to get ulcerative colitis under control; Lotemax gel for post-operative inflammation and pain; Arestin, a subgingival sustained-release antibiotic; PreserVision, an antioxidant eye vitamin and mineral supplement; CeraVe to rebuild and repair the skin barrier; Biotrue for healthy contact lens wear; and ReNu Multiplus to lubricate and rewet soft contact lenses. In addition, the company offers Ocuvite, a lutein eye vitamin and mineral supplement; Boston, a cleansing solution for gas permeable contact lenses; Artelac to treat dry eyes; various ophthalmic surgical products; SofLens daily disposable contact lenses; Biotrue ONEday lens; Bausch + Lomb Ultra, a contact lens PureVision, a contact lens; and medical device systems for aesthetic applications. Further, it provides Tobramycin and Dexamethasone ophthalmic suspension for steroid responsive inflammatory ocular conditions; Metronidazole to treat bacterial infections; and Latanoprost for the treatment of glaucoma. The company was formerly known as Biovail Corporation and changed its name to Valeant Pharmaceuticals International, Inc. in September, 2010. The company was founded in 1983 and is based in Laval, Canada.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Ross Thomas W. Sr.DirectorDec 14Buy14.735,00073,65026,822Dec 16 04:19 PM
Pershing Square Capital ManageDirectorDec 12Sale14.853,476,69051,628,84718,114,432Dec 13 04:14 PM
KARABELAS ARGERIS NDirectorAug 11Buy24.654,00098,60020,726Aug 12 04:37 PM
Ross Thomas W. Sr.DirectorJun 13Buy24.404,00097,60021,882Jun 27 03:40 PM
PAPA JOSEPH CCHAIRMAN & CEOJun 10Buy24.48202,0004,944,9602,442,199Jun 13 06:47 AM